FDA concerns about PRC2 complex inhibition & potential secondary hematologic malignancies, with both EZH2- & EED-targeting, due to Ipsen’s Tazverik, ended Fulcrum’s pociredir development & now there’s a partial hold on 2 Daiichi Sankyo valemetostat trials. https://t.co/TA9rbN5cID
This is some of the most valuable hantavirus information I’ve seen yet. And important to see in a region with many thousands of cruise ship visitors annually.
Hearing a lot about Hantavirus lately? While locally and in California, we don't see the Andes virus you're hearing about in the news, we monitor regularly for the Sin Nombre virus which does not spread person to person. More: https://t.co/WbLwvAnjdQ
$XBI is down 2.5% today and 0.7% year-to-date after the Fed held interest rates steady. It’s been a volatile year so far for biopharma after an optimistic start to 2025.
The scariest consequence of climate change yet … 😬😳🐍 This assuages my guilt somewhat that it’s warmer here than almost anywhere in the US right now. Stay cool San Diego.
Does anyone have good suggestions for organizations or advocacy groups that can offer advice on options for assisted living or group home care for elderly, disabled couples, including a veteran, who would not meet low income standards but also are not wealthy?
US IPO Week Ahead: At least 7 sizable IPOs teed up in one of the busiest weeks in four years $MANE $BOBS $EIKN $FPS $LFTO $IPO #IPO https://t.co/m7v9O7WvC2